A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension.
Saved in:
| Title: | A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension. |
|---|---|
| Authors: | Schachar, Ronald A.1 (AUTHOR) ronald.schachar@pfizer.com, Raber, Susan1 (AUTHOR), Courtney, Rachel1 (AUTHOR), Zhang, Min1 (AUTHOR) |
| Source: | Current Eye Research. Sep2011, Vol. 36 Issue 9, p809-817. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 02713683 |
|---|---|
| DOI: | 10.3109/02713683.2011.593725 |
